Loading
Latest filing published 04 Feb 2020 for IMMUNE PHARMACEUTICALS INC, €237.
Based on 7 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Anthony S. Fiorino discloses dealings in 3 companies, chiefly Brainstorm Cell Therapeutics Inc., Immune Pharmaceuticals Inc and Navidea Biopharmaceuticals, Inc. We count 12 filings; the first trade dates from 12 September 2014 and the latest from 3 February 2020.
Both buying and selling appear: 9 purchases worth €24k, against 1 sale worth €237. On balance, insiders were net buyers of €24k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants. In 2020 alone, the filings show no purchases and 1 sale.
In size, the median ticket on the buying side is €1,111. After 7 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -14.6%. This is a record of the past, not a forecast.
The record was last updated on 4 February 2020 with an open-market sale (€237) in Immune Pharmaceuticals Inc. The latest purchase dates back some time: it was published 3,076 days ago, on 23 May 2018. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations